Riskpilot← Back to searchSign inGet full accessLiby, Rönndahl&Cange Holding AB
ABActiveOrg 5592391576Economic activity was not specified by tax authority · NACE 0000Est. 20200 employees
Revenue 2025
SEK 0
EBITDA margin
—
-100% vs 2024
Equity ratio
57.3%
Financial strength
Net profit 2025
SEK 2,3M
-25% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -2K | -100% |
| Net profit | SEK 2,3M | -25% |
| Total assets | SEK 8,3M | -12% |
| Equity | SEK 4,8M | -5% |
| Employees | 0 | — |
Legal name
Liby, Rönndahl&Cange Holding AB
Org number
5592391576
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
28 januari 2020
Share capital
SEK 60 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska bedriva hälsovård, sjukvård, friskvård, kliniska prövningar, undervisning och utbildning inom medicinska området, äga och förvalta aktier och andra värdepapper samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −11 | −15 | −1 | −2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −11 | −15 | −1 | −2 |
| Net financials | −270 | 2 894 | 1 413 | 2 758 | 1 929 |
| Profit before tax | 3 130 | 2 994 | 1 533 | 2 988 | 2 250 |
| Tax | −670 | −0 | −0 | −0 | −0 |
| Net profit | 2 460 | 2 994 | 1 533 | 2 988 | 2 250 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 8 860 | 9 065 | 7 912 | 9 521 | 8 349 |
| Equity | 2 520 | 4 514 | 4 047 | 5 034 | 4 785 |
| Long-term debt | 5 400 | 3 876 | 3 865 | 4 465 | 3 543 |
| Short-term debt | 940 | 676 | 0 | 22 | 22 |
| Total debt | 6 340 | 4 552 | 3 865 | 4 487 | 3 565 |
EBITDA margin
-200000.0%
This company
15.8%
Market median
-1265923% vs market
20212025
Equity ratio
57.3%
This company
38.2%
Market median
+50% vs market
20212025
Return on equity
47.0%
This company
18.4%
Market median
+155% vs market
20212025
Net profit margin
225000000.0%
This company
8.1%
Market median
+2777777678% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.74×
This company
0.62×
Market median
+19% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-01-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SA | Audit | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Liby, Rönndahl&Cange Holding AB 
Liby&Rönndahl Läkarmottagning ABBoard members of Liby, Rönndahl&Cange Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stellan Anders Jeanson | Audit | 0 companies |
| Ingrid Charlotte Elisabeth Rönndahl | Deputy Board Member | 0 companies |
| Hedda Haugen Cange | Deputy Board Member | 0 companies |
| Jan Lars Bertil Rönndahl | Chairman | 0 companies |
| Jan-Eric Friis-Liby | Board of Directors | 0 companies |
| Lars Ingvar Cange | Board of Directors | 0 companies |